Six-month, prospective, longitudinal, open-Label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1687-1699

  Kennedy, Mary Jayne ^a   Davis, Daniel A ^a   Smith, Ned ^a   Gaedigk, Andrea ^b,c   Pearce, Robin E ^b,c   Kearns, Gregory L ^b,c  

^a University of Louisville School of Medicine   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytochrome P450; drug metabolism; growth hormone; pediatric

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; GUAIFENESIN; HUMAN GROWTH HORMONE; SOMATOMEDIN C; XANTHINE OXIDASE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; FEMALE; GENOTYPE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MALE; OPEN STUDY; PHENOTYPE;

ADOLESCENT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DWARFISM, PITUITARY; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; PHENOTYPE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; XANTHINE OXIDASE;

EID: 53049099182     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.012     Document Type: Article

References (47)

1. Lindsay R., Feldcamp M., Harris D., et al. Utah Growth Study: Growth standards and the prevalence of growth hormone deficiency. J Pediatr 125 (1994) 29-35
2. Frindik J.P., Kemp S.F., Kearns F.S., and Hale R.A. Etiologies of short stature among children in public growth screening clinics. Clin Res 38 (1990) 57A Abstract
3. Wilson T.A., Rose S.R., Cohen P., et al., for the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of the guidelines for the use of growth hormone in children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 143 (2003) 415-421
4. Redmond G.P., Bell J.J., and Perel J.M. Effect of human growth hormone on amobarbital metabolism in children. Clin Pharmacol Ther 24 (1978) 213-218
5. Rifkind A.B., Saenger P., Levine L.S., et al. Effects of growth hormone on antipyrine kinetics in children. Clin Pharmacol Ther 30 (1981) 127-132
6. Redmond G.P., Bell J.J., Nichola P.S., and Perel J.M. Effect of growth hormone on human drug metabolism: Time course and substrate specificity. Pediatr Pharmacol (New York) 1 (1980) 63-70
7. Rost K.L., and Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 55 (1994) 402-411
8. Balis F.M., Holcenberg J.S., Zimm S., et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 41 (1987) 384-387
9. 2 breath test. Dev Pharmacol Ther 12 (1989) 90-95
10. Mayayo-Sinués E., Fanlo A., Sinués B., et al. Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children. Eur J Clin Pharmacol 62 (2006) 123-127
11. Sinués B., Mayayo E., Fanlo A., et al. Effects of growth hormone deficiency and rhGH replacement therapy on the 6beta-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children. Eur J Clin Pharmacol 60 (2004) 559-564
12. Michalets E.L. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18 (1998) 84-112
13. Pacher P., Nivorozhkin A., and Szabó C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58 (2006) 87-114
14. Gaedigk A., Simon S.D., Pearce R.E., et al. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83 (2008) 234-242
15. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Allele nomenclature for CYP450 enzymes
16. http://www.cypalleles.ki.se Accessed July 1, 2008
17. Grant D.M., Tang B.K., and Kalow W. A simple test for acetylator phenotyping using caffeine. Br J Clin Pharmacol 17 (1984) 459-464
18. Blake M.J., Gaedigk A., Pearce R.E., et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81 (2007) 510-516
19. Campbell M.E., Spielberg S.P., and Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42 (1987) 157-165
20. Tang B.K., Kadar D., Qian L., et al. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49 (1991) 648-657
21. Grant D.M., Tang B.K., Campbell M.E., and Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 21 (1986) 454-458
22. Schmid B., Bircher J., Preisig R., and Küpfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38 (1985) 618-624
23. Dupont W.D., and Plummer Jr. W.D. PS power and sample size program available for free on the Internet. Controlled Clin Trials 18 (1997) 274
24. Kashuba A.D., Bertino Jr. J.S., Kearns G.L., et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phaseonCYP1A2, N-acetyltransferase-2, and xanthine oxidase activity as determined with caffeine phenotyping. Clin Pharmacol Ther 63 (1998) 540-551
25. Kennedy M.J., Abdel-Rahman S.M., Kashuba A.D., and Leeder J.S. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 44 (2004) 708-714
26. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc 32 (1937) 675-701
27. Zar J.H. Biostatistical Analysis. 3rd ed (1996), Prentice Hall, Upper Saddle River, NJ
28. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 62 (1967) 626-633
29. Cheung N.W., Liddle C., Coverdale S., et al. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 81 (1996) 1999-2001
30. Kashuba A.D., Nafziger A.N., Kearns G.L., et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8 (1998) 403-410
31. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling (September 2006), US Food and Drug Administration, Rockville, Md
32. Abdel-Rahman S.M., Gotschall R.R., Kauffman R.E., et al. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 65 (1999) 465-472
33. Jaffe C.A., Turgeon D.K., Lown K., et al. Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab 283 (2002) E1008-E1015
34. 2 breath test. Pediatr Res 23 (1988) 632-636
35. Kalow W., and Tang B.K. The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 53 (1993) 503-514
36. Philpot R.M., and Smith B.R. Role of cytochrome P-450 and related enzymes in the pulmonary metabolism of xenobiotics. Envir Health Perspect 55 (1984) 359-367
37. Bussières L., Souberbielle J.C., Pinto G., et al. The use of insulin-like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children. Clin Endocrinol (Oxf ) 52 (2000) 735-739
38. Ribela M.T., Gout P.W., and Bartolini P. Synthesis and chromatographic purification of recombinant human pituitary hormones. J Chromatogr B Analyt Technol Biomed Life Sci 790 (2003) 285-316
39. Kearns G.L., Kemp S.F., and Frindik J.P. Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. J Clin Endocrinol Metab 72 (1991) 1148-1156
40. Shapiro B.H., Agrawal A.K., and Pampori N.A. Gender differences in drug metabolism regulated by growth hormone. Int J Biochem Cell Biol 27 (1995) 9-20
41. van den Berg G., Veldhuis J.D., Frölich M., and Roelfsema F. An amplitudespecific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81 (1996) 2460-2467
42. Watkins P.B., Turgeon D.K., Jaffe C.A., et al. Pulsation frequency of growth hormone may mediate gender differences in CYP3A activity in man. Clin Res 41 (1993) 132 Abstract
43. Dhir R.N., Dworakowski W., Thangavel C., and Shapiro B.H. Sexually dimorphic regulation of isoforms of human cytochrome P450 by growth hormone. J Pharmacol Exp Ther 316 (2006) 87-94
44. Jürgens G., Lange K.H., Reuther L., et al. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 71 (2002) 162-168
45. Landin-Wilhelmsen K., Lundberg P.A., Lappas G., and Wilhelmlsen L. Insulin-like growth factor I levels in healthy adults. Horm Res 62 Suppl 1 (2004) 8-16
46. Bartke A. Growth hormone and aging. Endocrine 8 (1998) 103-108
47. Dahn M.S., and Lange M.P. Systemic and splanchnic metabolic response to exogenous human growth hormone. Surgery 123 (1998) 528-538